Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Fresenius SE & Co KGaA (FREG.DE)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (€)	Price Target (€)	Rating
2021-08-20	46.24	43.00	Neutral
2021-09-01	44.10	45.00	Neutral
2021-11-05	39.70	42.00	Neutral
2022-03-15	31.20	30.00	Neutral
2022-11-02	23.29	24.00	Neutral
2022-11-28	25.84	30.50	Buy
2023-01-06	28.63	32.50	Buy
2023-11-09	25.51	34.00	Buy

Disclosures

UBS has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
UBS Europe SE is acting as a sole financial advisor to Fresenius on Sale of a Majority Stake in Vamed's Rehabilitation Business To Pai Partners
Within the past 12 months, UBS has received compensation for investment banking services from this company/entity or one of its affiliates.
UBS expects to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.